source
- Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drugSentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.Fierce Biotech · 10h ago↗ source
- Abbott teams with Google Health on AI-powered health insights appTwo giants of their respective fields, Abbott and Google, are joining forces for a first-of-its-kind team-up that aims to build out a digital picture of people’s health.Fierce Biotech · 17h ago↗ source
- FDA issues early alert after BD needle set defects linked to four deathsThe FDA’s Center for Devices and Radiological Health released an early alert warning clinicians to stop using Becton Dickinson’s intraosseous vascular access needle sets after reports of serious in…